Mobile Technologies Extending Reach of Primary Care for Substance-Use-Disorders (R43/R44 Clinical Trial Optional)
The summary for the Mobile Technologies Extending Reach of Primary Care for Substance-Use-Disorders (R43/R44 Clinical Trial Optional) grant is detailed below.
This summary states who is eligible for the grant, how much grant money will be awarded, current and past deadlines, Catalog of Federal Domestic Assistance (CFDA) numbers, and a sampling of similar government grants.
Verify the accuracy of the data FederalGrants.com provides by visiting the webpage noted in the Link to Full Announcement section or by contacting the appropriate person listed as the Grant Announcement Contact.
If any section is incomplete, please visit the website for the National Institutes of Health, which is the U.S. government agency offering this grant.
Mobile Technologies Extending Reach of Primary Care for Substance-Use-Disorders (R43/R44 Clinical Trial Optional): Develop and test a prototype mobile/tablet technology-based application suitable for U.S. primary care settings, to serve as a low-cost user-friendly tool that primary care providers (PCPs) may use to deliver timely tailored feedback to patients following up on interventions for risky substance use. The feedback delivered should make sure patients engage in appropriate self-monitoring and self-management skills in adherence to treatment plans delivered during interventions for problematic substance use. Patients answers should inform delivery of tailored feedback (matching level of problematic substance-use risk as determined by validated screening and assessment tools) supporting health-promotion behaviors, such as helping patients adhere to evidence-based motivational interviewing or other behavioral therapy principles. The application also should track health action items completed, such as linkage to indicated follow-up treatment. It should be designed with a specific aim of improving coordination and delivery of indicated services to primary care patients at risk of developing substance use disorders (SUD).
Federal Grant Title: | Mobile Technologies Extending Reach of Primary Care for Substance-Use-Disorders (R43/R44 Clinical Trial Optional) |
Federal Agency Name: | National Institutes of Health (HHS-NIH11) |
Grant Categories: | Education Health |
Type of Opportunity: | Discretionary |
Funding Opportunity Number: | RFA-DA-19-021 |
Type of Funding: | Grant |
CFDA Numbers: | 93.279 |
CFDA Descriptions: | Information not provided |
Current Application Deadline: | March 19th, 2019 |
Original Application Deadline: | March 19th, 2019 |
Posted Date: | January 9th, 2019 |
Creation Date: | January 9th, 2019 |
Archive Date: | April 24th, 2019 |
Total Program Funding: | |
Maximum Federal Grant Award: | |
Minimum Federal Grant Award: | |
Expected Number of Awards: | |
Cost Sharing or Matching: | No |
Last Updated: | January 9th, 2019 |
- Applicants Eligible for this Grant
- Small businesses
- Additional Information on Eligibility
- Other Eligible Applicants include the following: Non-domestic (non-U.S.) Entities (Foreign Institutions) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, may be allowed. see the funding announcement for eligibility details
- Link to Full Grant Announcement
- http://grants.nih.gov/grants/guide/rfa-files/RFA-DA-19-021.html
- Grant Announcement Contact
- NIH OER Webmaster
[email protected]
If you have any problems linking to this funding announcement, please contact the NIH OER Webmaster - Similar Government Grants
- • Research on the Neuro-Immune Axis in the context of HIV and Substance Use (R01 Clinical Tr...
- • Research on the Neuro-Immune Axis in the Context of HIV and Substance Use (R21 Clinical Tr...
- • Developing Digital Therapeutics for Substance Use Disorders (UG3/UH3 Clinical Trial option...
- • Transformative Research on the Basic Mechanisms of Polysubstance use in Addiction (R01 - C...
- • Mechanistic Studies on Social Behavior in Substance Use Disorder (R01 Clinical Trials Not ...
- • NIDA Phase II Small Business Innovation Research (SBIR [R44]) Competing Renewal Awards
- • Drug Abuse Aspects of Hiv/Aids and Other Infections
- • Epidemiology of Drug Abuse
- More Grants from the National Institutes of Health
- • Feasibility of Novel Diagnostics for TB in Endemic Countries (FEND for TB) (R01 Clinical ...
- • Specialized Programs of Research Excellence (SPOREs) in Cancer Health Disparities and Mino...
- • Strategies for Controlled Release of HIV Vaccines (SCORE-H) (R01 Clinical Trial Not Allowe...
- • NINDS Program Project Grant (P01 Clinical Trial Optional)
- • Centers for Research in Emerging Infectious Diseases (CREID) Network (U01 Clinical Trial N...